www.fdanews.com/articles/137585-new-study-of-seraph-affinity-apheresis-device-demonstrates-potential-for-reducing-the-high-death-rate-from-sepsis-a-top-10-cause-of-death-in-the-u-s
New Study of Seraph Affinity Apheresis Device Demonstrates Potential for Reducing the High Death Rate from Sepsis, a Top-10 Cause of Death in the U.S.
June 13, 2011
ExThera Medical Corporation announced Monday that a new study of its breakthrough Seraph (Selective Removal by Apheresis) affinity therapy device demonstrates its potential as a treatment for patients suffering from Staphylococcus aureus- and/or Methicillin-Resistant S. aureus (MRSA)-induced sepsis.
CNBC
CNBC